Company Analysis
Sign in

Serina Therapeutics, Inc. (SER)

NYSE: SER · Pharmaceutical Preparations · Huntsville, AL · filing with the SEC since 2017
Full chart Alerts Compare
Grade4.4
◀ Past 5.1● Present 2.0▶ Future 6.0
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

27 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Serina Therapeutics, Inc.’s names, not what it holds today.

Patents granted
27
27 utility, 1976 to Dec 31, 2025
Granted in 2025
2
Against 3 in 2024 and 1 in 2023
Applications published
53
2 of them in 2025
Names they are printed under
4
its own name, a former name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals10
Biotechnology1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
Serina Therapeutics, Inc. its own name
US, as the owner printed on each patent
23 granted
18 published
Serina Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
15 published
AgeX Therapeutics, Inc. a former name
US, as the owner printed on each patent
4 granted
8 published
AgeX Therapeutics, Inc. a former name
named as the applicant on its applications, in US
0 granted
12 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Sep 2, 202512,404,493Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cellsBiotechnologyAgeX Therapeutics, Inc.
Feb 25, 202512,233,132Polyoxazoline-lipid conjugates and lipid nanoparticles and pharmaceutical compositions including samePharmaceuticalsSerina Therapeutics, Inc.
May 7, 202411,977,073HLA G-modified cells and methodsPharmaceuticalsAgeX Therapeutics, Inc.
Apr 2, 202411,944,618Subcutaneous delivery of polymer conjugates of therapeutic agentsPharmaceuticalsSerina Therapeutics, Inc.
Mar 12, 202411,925,689Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the samePharmaceuticalsSerina Therapeutics, Inc.
Sep 26, 202311,766,432Cleavable conjugates of catechol compounds and water-soluble polymers and methods of treatment using the samePharmaceuticalsSerina Therapeutics, Inc.
Apr 12, 202211,298,350Subcutaneous delivery of polymer conjugates of therapeutics agentsPharmaceuticalsSerina Therapeutics, Inc.
Jan 18, 202211,224,595Subcutaneous delivery of poly(oxazoline) polymer conjugatesPharmaceuticalsSerina Therapeutics, Inc.
Jan 4, 202211,213,588Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the samePharmaceuticalsSerina Therapeutics, Inc.
Jul 20, 202111,065,340Polyoxazoline antibody drug conjugatesPharmaceuticalsSerina Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Nov 13, 20252025/0346862METHODS FOR THE RE-DERIVATION OF DIVERSE PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLSBiotechnologyAgeX Therapeutics, Inc.
Jul 3, 20252025/0216377COMPOSITIONS AND METHODS FOR DETECTING CARDIOTOXICITYAnalysis of biological materialsAgeX Therapeutics, Inc.
Oct 24, 20242024/0350553METHODS FOR MODULATING THE REGENERATIVE PHENOTYPE IN MAMMALIAN CELLSBiotechnologyAgeX Therapeutics, Inc.
Aug 22, 20242024/0277821TARGETING OF ANTIGEN-PRESENTING CELLS BY NANOPARTICLES CONTAINING POLYOXAZOLINE-LIPID CONJUGATESPharmaceuticalsSerina Therapeutics, Inc.
May 16, 20242024/0158788METHODS AND COMPOSITIONS USED TO MODIFY CHROMATIN ARCHITECTURE TO REGULATE PHENOTYPE IN AGING AND CANCERPharmaceuticalsAgeX Therapeutics, Inc.
Apr 4, 20242024/0108750POLYOXAZOLINE-LIPID CONJUGATES AND LIPID NANOPARTICLES AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAMEPharmaceuticalsSerina Therapeutics, Inc.
Feb 29, 20242024/0066070METHODS FOR THE EX VIVO INDUCTION OF TISSUE REGENERATION IN MICROBIOPSIESMedical technologyAgeX Therapeutics, Inc.
Jan 18, 20242024/0016798CLEAVABLE CONJUGATES OF CATECHOL COMPOUNDS AND WATER-SOLUBLE POLYMERS AND METHODS OF TREATMENT USING THE SAMEPharmaceuticalsSerina Therapeutics, Inc.
Mar 23, 20232023/0093399METHODS FOR GENERATING PLURIPOTENT STEM CELL-DERIVED BROWN FAT CELLSBiotechnologyAgeX Therapeutics, Inc.
Jan 12, 20232023/0009076POLYOXAZOLINE-DRUG CONJUGATES WITH NOVEL PHARMACOKINETIC PROPERTIESPharmaceuticalsSerina Therapeutics, Inc. · patent 12,485,181 granted from it
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Biotechnology 2 · Medical technology 1 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton SER · research, not advice